About Benazepril

Benazepril is a prodrug that inhibits the conversion of angiotensin-I to angiotensin-II by inhibiting angiotensin-converting enzyme (ACE) after being hydrolyzed in the liver to benazeprilat. 

ACEi-induced reduction in intraglomerular hypertension occurs because of a vasodilating effect on efferent glomerular arterioles. This has a proteinuric-reducing effect; however, an increase in serum creatinine concentration may accompany any reduction in glomerular hypertension.

• Proteinuria Reduction: 0.5 mg/kg, PO, q24h gradually increased by 0.5 mg/kg.PO, q24h to a maximum of 2 mg/kg, PO, q24h. Total daily doses can be divided and administered q12h.

• Multi-Modal Use: Benazepril therapy with telmisartan may result in better outcomes than benazepril alone  (Fowler BL, Stefanovski D, Hess RS, McGonigle K. Effect of telmisartan, angiotensin-converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs. J Vet Intern Med. 2021;35(3):7).

• Therapeutic Aim: Decreasing proteinuria preferably to <0.5) (i.e., urinary protein-to-creatinine [UPC] ratio decreased by ≥50%).